Valneva SE (VLA.PA)
EUR 3.17
(-0.63%)
EUR 3.17
(-0.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 52.83 Million EUR | 31.67% |
| 2022 | 36.86 Million EUR | -76.98% |
| 2021 | 160.16 Million EUR | 185.91% |
| 2020 | 56.01 Million EUR | -26.51% |
| 2019 | 76.22 Million EUR | 9.52% |
| 2018 | 69.6 Million EUR | 17.35% |
| 2017 | 59.31 Million EUR | 16.33% |
| 2016 | 50.98 Million EUR | 62.39% |
| 2015 | 31.39 Million EUR | 58.74% |
| 2014 | 19.77 Million EUR | 41.92% |
| 2013 | 13.93 Million EUR | 281.85% |
| 2012 | -7.66 Million EUR | -316.44% |
| 2011 | 3.54 Million EUR | 90.79% |
| 2010 | 1.85 Million EUR | 185.89% |
| 2009 | -2.16 Million EUR | -421.1% |
| 2008 | 673 Thousand EUR | 182.37% |
| 2007 | -817 Thousand EUR | -150.97% |
| 2006 | 1.6 Million EUR | -36.79% |
| 2005 | 2.53 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 14.59 Million EUR | 37.75% |
| 2024 Q1 | 10.59 Million EUR | -33.1% |
| 2023 Q2 | 6.87 Million EUR | -47.21% |
| 2023 Q4 | 15.83 Million EUR | -7.4% |
| 2023 Q3 | 17.09 Million EUR | 148.64% |
| 2023 FY | 48.53 Million EUR | 31.67% |
| 2023 Q1 | 13.02 Million EUR | 226.31% |
| 2022 Q4 | -10.31 Million EUR | -108.22% |
| 2022 Q1 | 7.98 Million EUR | -96.8% |
| 2022 FY | 36.86 Million EUR | -76.98% |
| 2022 Q3 | 125.43 Million EUR | 245.44% |
| 2022 Q2 | -86.24 Million EUR | -1179.66% |
| 2021 Q2 | 4.15 Million EUR | -51.46% |
| 2021 Q3 | -102.46 Million EUR | -2564.21% |
| 2021 Q4 | 249.9 Million EUR | 343.9% |
| 2021 FY | 160.16 Million EUR | 185.91% |
| 2021 Q1 | 8.56 Million EUR | -73.49% |
| 2020 Q4 | 32.31 Million EUR | 1155.95% |
| 2020 Q3 | -3.06 Million EUR | -184.23% |
| 2020 Q2 | 3.63 Million EUR | -84.3% |
| 2020 FY | 56.01 Million EUR | -26.51% |
| 2020 Q1 | 23.13 Million EUR | -18.08% |
| 2019 Q4 | 28.24 Million EUR | 70.42% |
| 2019 Q1 | 22.62 Million EUR | -3.85% |
| 2019 Q2 | 8.79 Million EUR | -61.15% |
| 2019 Q3 | 16.57 Million EUR | 88.52% |
| 2019 FY | 76.22 Million EUR | 9.52% |
| 2018 Q1 | 19.04 Million EUR | 29.15% |
| 2018 FY | 69.6 Million EUR | 17.35% |
| 2018 Q4 | 23.53 Million EUR | 111.49% |
| 2018 Q3 | 11.12 Million EUR | -30.03% |
| 2018 Q2 | 15.9 Million EUR | -16.48% |
| 2017 Q1 | 15.12 Million EUR | 16.91% |
| 2017 FY | 59.31 Million EUR | 16.33% |
| 2017 Q4 | 14.74 Million EUR | -2.69% |
| 2017 Q3 | 15.15 Million EUR | 5.97% |
| 2017 Q2 | 14.29 Million EUR | -5.46% |
| 2016 Q1 | 10.82 Million EUR | -7.46% |
| 2016 FY | 50.98 Million EUR | 62.39% |
| 2016 Q4 | 12.93 Million EUR | 28.02% |
| 2016 Q3 | 10.1 Million EUR | -40.98% |
| 2016 Q2 | 17.12 Million EUR | 58.14% |
| 2015 Q3 | 9.54 Million EUR | 64.69% |
| 2015 Q4 | 11.69 Million EUR | 22.54% |
| 2015 FY | 31.39 Million EUR | 58.74% |
| 2015 Q2 | 5.79 Million EUR | 33.11% |
| 2015 Q1 | 4.35 Million EUR | -3.24% |
| 2014 FY | 19.77 Million EUR | 41.92% |
| 2014 Q4 | 4.5 Million EUR | -7.16% |
| 2014 Q3 | 4.84 Million EUR | -25.5% |
| 2014 Q2 | 6.5 Million EUR | 65.91% |
| 2014 Q1 | 3.92 Million EUR | 53.74% |
| 2013 Q3 | 7.2 Million EUR | 108.79% |
| 2013 FY | 13.93 Million EUR | 281.85% |
| 2013 Q1 | -2.08 Million EUR | -47.28% |
| 2013 Q2 | 3.44 Million EUR | 265.26% |
| 2013 Q4 | 2.55 Million EUR | -64.57% |
| 2012 Q4 | -1.41 Million EUR | -237.31% |
| 2012 Q3 | 1.03 Million EUR | 0.0% |
| 2012 FY | -7.66 Million EUR | -316.44% |
| 2011 FY | 3.54 Million EUR | 90.79% |
| 2010 FY | 1.85 Million EUR | 185.89% |
| 2009 FY | -2.16 Million EUR | -421.1% |
| 2008 FY | 673 Thousand EUR | 182.37% |
| 2007 FY | -817 Thousand EUR | -150.97% |
| 2006 FY | 1.6 Million EUR | -36.79% |
| 2005 FY | 2.53 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -8449.676% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -1249.949% |
| Adocia SA | 1.38 Million EUR | -3714.946% |
| Aelis Farma SA | 12.35 Million EUR | -327.553% |
| Biophytis S.A. | -803 Thousand EUR | 6679.95% |
| Advicenne S.A. | 1.42 Million EUR | -3605.259% |
| genOway Société anonyme | 20.1 Million EUR | -162.866% |
| IntegraGen SA | 5.01 Million EUR | -952.891% |
| Medesis Pharma S.A. | -2.66 Million EUR | 2082.799% |
| Neovacs S.A. | 29.31 Thousand EUR | -180144.934% |
| NFL Biosciences SA | -56.06 Thousand EUR | 94344.078% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -2354.205% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 3822.78% |
| Sensorion SA | 3.78 Million EUR | -1294.903% |
| Theranexus Société Anonyme | -4.63 Million EUR | 1239.05% |
| TME Pharma N.V. | -127 Thousand EUR | 41703.937% |
| Valbiotis SA | 2.66 Million EUR | -1880.397% |
| TheraVet SA | -530.79 Thousand EUR | 10054.295% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -4070.245% |
| DBV Technologies S.A. | 4.15 Million EUR | -1170.245% |
| Genfit S.A. | 28.22 Million EUR | -87.206% |
| GeNeuro SA | -293.8 Thousand EUR | 18084.003% |
| Innate Pharma S.A. | -4.12 Million EUR | 1382.14% |
| Inventiva S.A. | 17.5 Million EUR | -201.926% |
| MaaT Pharma SA | 1.65 Million EUR | -3092.568% |
| MedinCell S.A. | 9.28 Million EUR | -468.874% |
| Nanobiotix S.A. | 36.2 Million EUR | -45.926% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -2272.564% |
| Poxel S.A. | 1000.00 EUR | -5283600.0% |
| GenSight Biologics S.A. | 3 Million EUR | -1661.233% |
| Transgene SA | -28.4 Million EUR | 286.02% |